Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,925.00
Bid: 1,925.00
Ask: 1,927.00
Change: -10.00 (-0.52%)
Spread: 2.00 (0.104%)
Open: 1,938.00
High: 1,942.00
Low: 1,924.00
Prev. Close: 1,935.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

9 May 2016 16:05

RNS Number : 6974X
Hikma Pharmaceuticals Plc
09 May 2016
 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

SAID DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 17,440 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

17,440

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£22.28p

14.

Date and place of transaction

 

9 MAY 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

13,177,501 (5.50%) COMPRISING:

 

DIRECTLY, INCLUDING CONNECTED PERSONS: 657,000 (0.27%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 12,520,501 (5.23%)

16.

Date issuer informed of transaction

 

 

9 MAY 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 9 May 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MAZEN DARWAZAH

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 17,440 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

17,440

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£22.28p

14.

Date and place of transaction

 

9 MAY 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

7,210,207 (3.01%) COMPRISING:

 

DIRECTLY: 907,041 (0.38%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 6,303,166 (2.63%)

16.

Date issuer informed of transaction

 

 

9 MAY 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 9 May 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

Annex DTR3

 

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons

 

 

All relevant boxes should be completed in block capital letters.

 

1.

Name of the issuer

 

HIKMA PHARMACEUTICALS PLC

2.

State whether the notification relates to (i) a

transaction notified in accordance with DTR 3.1.2 R,

(ii) a disclosure made in accordance

LR 9.8.6R(1) or

(iii) a disclosure made in accordance with section 793 of the Companies Act (2006).

 

(i) & (iii)

3.

Name of person discharging managerial

responsibilities/director

 

MOHAMMED 'ALI' AL-HUSRY

 

4.

State whether notification relates to a person

connected with a person discharging managerial responsibilities/director named in 3 and identify the connected person

 

N/A

 

5.

Indicate whether the notification is in respect of a holding of the person referred to in 3 or 4 above or in respect of a nonbeneficial

interest 1

 

3 ABOVE

 

6.

Description of shares (including class), debentures or derivatives or financial instruments relating to shares

 

ORDINARY SHARES OF 10P EACH

 

7.

Name of registered shareholders(s) and, if more than one, the number of shares held by each of them

 

VIDACOS NOMINEES LIMITED ON BEHALF OF DARHOLD LIMITED

 

8.

State the nature of the transaction

 

PURCHASE OF 17,440 BY DARHOLD LIMITED, IN WHICH THE PDMR HAS AN EQUITY STAKE.

9.

Number of shares, debentures or financial

instruments relating to shares acquired

 

17,440

10.

Percentage of issued class acquired (treasury shares of that class should not be taken into account when calculating percentage)

0.01%

 

11.

Number of shares, debentures or financial

instruments relating to shares disposed

 

N/A

12.

Percentage of issued class disposed (treasury shares of that class should not be taken into account when calculating percentage)

 

N/A

 

13.

Price per share or value of transaction

 

£22.28p

14.

Date and place of transaction

 

9 MAY 2016, LONDON

 

15.

Total holding following notification and total percentage holding following notification (any treasury shares should not be taken into account when calculating percentage)

 

5,796,669 (2.42%) UNDER DYKB LIMITED COMPRISING:

 

DIRECTLY: 1,162,811 (0.49%)

 

INDIRECTLY THROUGH DARHOLD LIMITED: 4,633,858 (1.93%)

16.

Date issuer informed of transaction

 

 

9 MAY 2016

 

If a person discharging managerial responsibilities has been granted options by the issuer

complete the following boxes

 

17.

Date of grant

 

 

N/A

18.

Period during which or date on which exercisable

 

N/A

19.

Total amount paid (if any) for grant of the option

 

N/A

20.

Description of shares or debentures involved (class and number)

 

N/A

21.

Exercise price (if fixed at time of grant) or

indication that price is to be fixed at the time of exercise

 

N/A

22.

Total number of shares or debentures over which options held following notification

 

 

N/A

23.

Any additional information

 

 

N/A

24.

Name of contact and telephone number for queries

 

PETER SPEIRS 0207 399 2772

 

 

 

Name of authorised official of issuer responsible for making notification

 

Peter Speirs, Company Secretary

 

Date of notification 9 May 2016

 

 

Notes: This form is intended for use by an issuer to make a RIS notification required by DR 3.3.

 

(1)

An issuer making a notification in respect of a transaction relating to the shares or debentures of the issuer should complete boxes 1 to 16, 23 and 24.

(2)

An issuer making a notification in respect of a derivative relating the shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and 24.

(3)

An issuer making a notification in respect of options granted to a director/person discharging managerial responsibilities should complete boxes 1 to 3 and 17 to 24.

(4)

An issuer making a notification in respect of a financial instrument relating to the shares of the issuer (other than a debenture) should complete boxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBUGDUXGGBGLC
Date   Source Headline
3rd Jan 20237:00 amRNSHikma launches sodium oxybate in the US
1st Dec 20229:24 amRNSTotal Voting Rights
30th Nov 20227:00 amRNSHikma Injectables Portugal site visit
22nd Nov 202211:38 amRNSHolding(s) in Company
17th Nov 20229:50 amRNSHolding(s) in Company
3rd Nov 20227:00 amRNSTrading Statement
13th Oct 20223:00 pmRNSDirectorate Change
5th Oct 202212:16 pmRNSHolding(s) in Company
4th Oct 202210:05 amRNSHolding(s) in Company
3rd Oct 20223:52 pmRNSBlock listing Interim Review
3rd Oct 20223:11 pmRNSTotal Voting Rights
30th Sep 20227:00 amRNSDirector changes and update on AGM 2022 resolution
14th Sep 20229:19 amRNSChange of Hikma interim dividend payment date
1st Sep 20222:25 pmRNSTotal Voting Rights
30th Aug 202212:22 pmRNSHikma launches RYALTRIS
23rd Aug 20223:12 pmRNSDirector/PDMR Shareholding
4th Aug 20227:00 amRNSHalf-year Report
1st Aug 20224:48 pmRNSTotal Voting Rights
18th Jul 20229:26 amRNSNotice of Results
1st Jul 202210:52 amRNSTotal Voting Rights
15th Jun 20223:00 pmRNSCompany Secretary Change
15th Jun 20221:46 pmRNSDirector/PDMR Shareholding
10th Jun 20226:08 pmRNSTransaction in Own Shares
9th Jun 20225:14 pmRNSTransaction in Own Shares
8th Jun 20225:15 pmRNSTransaction in Own Shares
7th Jun 20225:13 pmRNSTransaction in Own Shares
6th Jun 20225:14 pmRNSTransaction in Own Shares
1st Jun 20226:08 pmRNSTransaction in Own Shares
31st May 20225:52 pmRNSTransaction in Own Shares
31st May 202210:00 amRNSDirector/PDMR Shareholding
30th May 20225:23 pmRNSTransaction in Own Shares
27th May 20225:20 pmRNSTransaction in Own Shares
26th May 20225:20 pmRNSTransaction in Own Shares
25th May 20226:03 pmRNSTransaction in Own Shares
24th May 20225:53 pmRNSTransaction in Own Shares
24th May 20227:00 amRNSSiggi Olafsson to step down as Chief Executive
23rd May 20225:51 pmRNSTransaction in Own Shares
20th May 20225:37 pmRNSTransaction in Own Shares
20th May 202212:58 pmRNSResults of EGM
19th May 20226:15 pmRNSTransaction in Own Shares
18th May 20225:22 pmRNSTransaction in Own Shares
17th May 20225:49 pmRNSTransaction in Own Shares
16th May 20226:05 pmRNSTransaction in Own Shares
13th May 20225:41 pmRNSTransaction in Own Shares
12th May 20225:35 pmRNSTransaction in Own Shares
11th May 20225:19 pmRNSTransaction in Own Shares
11th May 20227:00 amRNSShare Buyback Programme
10th May 20225:18 pmRNSTransaction in Own Shares
9th May 20225:59 pmRNSTransaction in Own Shares
6th May 20225:54 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.